Search Results - "Labrot E"

Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.

Authors: Pitt JJ Riester M Zheng Y et al.

Source: Nature communications [Nat Commun] 2019 Jan 14; Vol. 10 (1), pp. 288. Date of Electronic Publication: 2019 Jan 14.

Publication Type: Journal Article; Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: PubMed not MEDLINE

This result is not displayed to guests.
Login for full access.

Targeting pancreatic cancer with combined inhibition of EGFR and RAF.

Authors: Brandstetter, Jakob Goldstein, Lea Schreiber, Tim et al.

Source: PLoS ONE. 4/24/2026, Vol. 21 Issue 4, p1-19. 19p.

Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort.

Authors: Song, Xiya Jin, Han Li, Xiangyu et al.

Source: PLoS Genetics. 7/7/2025, Vol. 21 Issue 7, p1-28. 28p.

Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers.

Authors: Lee, Ji Yoon Lee, Ji Won Chung, Min Sung et al.

Source: BMC Medicine. 9/27/2024, Vol. 22 Issue 1, p1-15. 15p.

Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.

Authors: Akinyemiju, Tomi Jones, Kelley Gupta, Anjali et al.

Source: BMC Cancer. 9/25/2021, Vol. 21 Issue 1, p1-13. 13p.

Targeting Drug-Tolerant Persister Cancer Cells: Can Nanomaterial-Based Strategies Be Helpful for Anti-DTP Therapies?

Authors: Ghoderao, Prachi Kwiatkowska-Borowczyk, Eliza Sahare, Sanjay et al.

Source: Pharmaceutics. Nov2025, Vol. 17 Issue 11, p1428. 27p.

Association of white matter hyperintensities with long‐term EGFR‐TKI treatment and prediction of progression risk.

Authors: Yang, Hang Meng, Rui Jiang, Junjie et al.

Source: Brain & Behavior. Dec2023, Vol. 13 Issue 12, p1-10. 10p.

HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.

Authors: Liu, Jie Wang, Wei Wang, Kunkun et al.

Source: Journal of Translational Medicine. 8/28/2024, Vol. 22 Issue 1, p1-14. 14p.

Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review.

Authors: Boichuk, Sergei Gessel, Tatyana

Source: Cancers. Oct2025, Vol. 17 Issue 20, p3354. 39p.

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.

Authors: Broghammer, Felix Korovina, Irina Gouda, Mahesh et al.

Source: Molecular Cancer. 2/21/2024, Vol. 23 Issue 1, p1-25. 25p.

Genomic features of rapid versus late relapse in triple negative breast cancer.

Authors: Zhang, Yiqing Asad, Sarah Weber, Zachary et al.

Source: BMC Cancer. 5/18/2021, Vol. 21 Issue 1, p1-13. 13p.

Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma.

Authors: Ma, Kai Wang, Youpeng Zhang, Yuanzheng et al.

Source: Cancers. Oct2022, Vol. 14 Issue 20, p5062-N.PAG. 13p.

Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.

Authors: Heil BN Baral G Pfeffer CM et al.

Source: Oncogene [Oncogene] 2026 Jun; Vol. 45 (20), pp. 1861-1873. Date of Electronic Publication: 2026 Apr 11.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Authors: Tiedt R King FJ Stamm C et al.

Source: Cell reports [Cell Rep] 2023 Apr 25; Vol. 42 (4), pp. 112297. Date of Electronic Publication: 2023 Mar 23.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE

Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics.

Authors: Chien-Yun Lee Matthew The Chen Meng et al.

Source: Molecular Systems Biology. 1/1/2024, Vol. 20 Issue 1, p28-55. 28p.

Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies.

Authors: García-Sancha, Natalia Corchado-Cobos, Roberto Pérez-Losada, Jesús

Source: International Journal of Molecular Sciences. Apr2025, Vol. 26 Issue 7, p2993. 32p.

Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.

Authors: Romaniello, Donatella Morselli, Alessandra Marrocco, Ilaria

Source: International Journal of Molecular Sciences. Apr2025, Vol. 26 Issue 7, p2957. 31p.

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Authors: Liao, Yan-You Tsai, Chia-Luen Huang, Hsiang-Po

Source: Cancers. Feb2025, Vol. 17 Issue 3, p459. 34p.

PELI1 and EGFR cooperate to promote breast cancer metastasis.

Authors: Qi, Jie Xu, Guangsen Wu, Xiaoxia et al.

Source: Oncogenesis. 2/25/2023, Vol. 12 Issue 1, p1-13. 13p.